pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

ambrx PRESS RELEASE ARCHIVE

Jun 30, 2021

Ambrx Appoints Sonja Nelson as Chief Financial Officer

Jun 17, 2021

Ambrx Announces Pricing of Initial Public Offering

Jun 10, 2021

Ambrx Announces Formation and Members of Scientific Advisory Board

Apr 14, 2021

Ambrx Appoints Olivia Ware and Katrin Rupalla to its Board of Directors

Mar 17, 2021

Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer

Feb 23, 2021

Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Jan 7, 2021

Ambrx Appoints Gary Yeung as Chief Financial Officer and Chief Operating Officer

Dec 10, 2020

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

Nov 9, 2020

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics

Jan 13, 2020

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

Dec 12, 2019

Zhejiang Medicine and Ambrx Present Positive Top Line Data from a Phase 1a/1b Clinical Trial of ARX788 in Metastatic HER2 Positive Breast Cancer

Oct 23, 2019

Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates

Jul 16, 2019

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

Dec 21, 2017

Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China

Jan 5, 2017

Ambrx and MabSpace Biosciences to Collaborate on Novel Antibody Drug Conjugates

Aug 17, 2016

Ambrx's Innovative Antibody Drug Conjugate (ADC) US IND Active

Aug 4, 2016

Ambrx closes $45M round of financing

Apr 19, 2016

Global Lipodystrophy Pipeline Review 2016 Featuring Aegerion Pharmaceuticals, Ambrx, Bolder Biotechnology, Galmed Pharma, Theratechnologies and Zydus Cadila Healthcare - Research and Markets

Mar 21, 2016

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

Nov 16, 2015

Ambrx Announces New Chief Medical Officer

Jun 19, 2015

Ambrx Names Dr. Tiecheng Qiao as CEO, Dr. Feng Tian as CSO

May 21, 2015

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

Apr 29, 2014

Ambrx and Zhejiang Hisun Pharmaceutical to Collaborate on the Development and Commercialization of Bispecifics for Cancer

Feb 24, 2014

Sheila Gujrathi, M.D., Joins Ambrx Board of Directors

Feb 5, 2014

Ambrx Appoints Barry Greene to Board of Directors

Aug 20, 2013

Ambrx Appoints Peter Kiener, Ph.D., as Chief Scientific Officer

Jun 17, 2013

Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer

Jun 16, 2013

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer

May 3, 2013

Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates

Apr 4, 2013

Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

Jan 7, 2013

Ambrx Appoints Lawson Macartney, Ph.D., DVM, Chief Executive Officer

Jun 18, 2012

Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates

Sep 22, 2011

Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure

Jun 22, 2011

Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences

May 25, 2011

Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology

Google Analytics Alternative